Daniel Couriel

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. pmc An unusual cause of alveolar hemorrhage post hematopoietic stem cell transplantation: a case report
    Sachin Gupta
    Department of Pulmonary Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    BMC Cancer 6:87. 2006
  2. ncbi Tumor necrosis factor-alpha blockade for the treatment of acute GVHD
    Daniel Couriel
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 104:649-54. 2004
  3. ncbi Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management
    Daniel Couriel
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Cancer 101:1936-46. 2004
  4. ncbi Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD
    Daniel R Couriel
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 423, Houston, TX 77030, USA
    Blood 107:3074-80. 2006
  5. ncbi Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working
    Daniel Couriel
    University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Biol Blood Marrow Transplant 12:375-96. 2006
  6. ncbi Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation
    Daniel R Couriel
    Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030 4095, USA
    Biol Blood Marrow Transplant 10:178-85. 2004
  7. doi Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS
    Borje S Andersson
    Department of Stem Cell Transplantation and Cellular Therapy, U T M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 423, Houston, TX 77030 4009, USA
    Biol Blood Marrow Transplant 14:672-84. 2008
  8. ncbi Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab
    Issa F Khouri
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Blood 111:5530-6. 2008
  9. ncbi Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia
    Partow Kebriaei
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Blood 110:3456-62. 2007
  10. ncbi Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS
    Marcos de Lima
    Department of Blood and Marrow Transplantation, MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 104:857-64. 2004

Detail Information

Publications42

  1. pmc An unusual cause of alveolar hemorrhage post hematopoietic stem cell transplantation: a case report
    Sachin Gupta
    Department of Pulmonary Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    BMC Cancer 6:87. 2006
    ..Diffuse alveolar hemorrhage associated with Strongyloides stercoralis hyperinfection in stem cell transplant patients has been rarely reported...
  2. ncbi Tumor necrosis factor-alpha blockade for the treatment of acute GVHD
    Daniel Couriel
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 104:649-54. 2004
    ..Survival after steroid-resistant acute GVHD continues to be problematic. The possibility of excessive fungal and other infections must be explored further...
  3. ncbi Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management
    Daniel Couriel
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Cancer 101:1936-46. 2004
    ..In this review, the authors summarize the most current knowledge on the pathophysiology, clinical manifestations, and management of this potentially life-threatening transplantation complication...
  4. ncbi Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD
    Daniel R Couriel
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 423, Houston, TX 77030, USA
    Blood 107:3074-80. 2006
    ..Objective responses were observed in a substantial number of patients with both skin and visceral chronic GVHD failing corticosteroids and other immunosuppression...
  5. ncbi Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working
    Daniel Couriel
    University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Biol Blood Marrow Transplant 12:375-96. 2006
    ..Optimal care of patients with chronic GVHD often requires a multidisciplinary approach...
  6. ncbi Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation
    Daniel R Couriel
    Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030 4095, USA
    Biol Blood Marrow Transplant 10:178-85. 2004
    ..It is interesting to note that nonrelapse mortality with nonmyeloablative regimens in older and more debilitated patients was low (14%) and comparable to that achieved with standard high-dose regimens in younger patients...
  7. doi Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS
    Borje S Andersson
    Department of Stem Cell Transplantation and Cellular Therapy, U T M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 423, Houston, TX 77030 4009, USA
    Biol Blood Marrow Transplant 14:672-84. 2008
    ..These results support replacing BuCy +/- ATG with Bu-Flu +/- rabbit-antithymocyte globulin (ATG), and warrant a prospective comparison between allogeneic HSCT and conventional induction/consolidation chemotherapy for AML in CR1...
  8. ncbi Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab
    Issa F Khouri
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Blood 111:5530-6. 2008
    ..Only 5 patients were still undergoing immunosuppressive therapy at the time of last follow-up. We believe that the described results are a step forward toward developing a curative strategy for recurrent follicular lymphoma...
  9. ncbi Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia
    Partow Kebriaei
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Blood 110:3456-62. 2007
    ..TRM rates are acceptable in this high-risk population but increase over time...
  10. ncbi Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS
    Marcos de Lima
    Department of Blood and Marrow Transplantation, MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 104:857-64. 2004
    ..The results suggest that intravenous busulfan-fludarabine is an efficacious, reduced-toxicity, myeloablative-conditioning regimen for patients with AML or MDS undergoing HSCT...
  11. ncbi Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias
    Marcos de Lima
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Cancer 97:1242-7. 2003
    ..Decitabine is a hypomethylating agent that has activity in patients with leukemia. The authors combined decitabine with busulfan and cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation...
  12. pmc Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study
    Simrit Parmar
    Department of Stem Cell Transplantation and Cell Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 423, Houston, TX 77030, USA
    J Clin Oncol 29:294-302. 2011
    ....
  13. pmc Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan
    Betul Oran
    M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Biol Blood Marrow Transplant 13:454-62. 2007
    ..Use of unrelated donors increased the risk of NRM only among patients with active disease. FM and HSCT elicited long-term disease control in a significant fraction of this high-risk cohort...
  14. ncbi Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma
    Muzaffar H Qazilbash
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:1084-9. 2006
    ..The outcomes of salvage autologous or allogeneic transplants were analyzed retrospectively in patients relapsing after an autograft...
  15. ncbi Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation
    Raymond Wong
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Biol Blood Marrow Transplant 11:108-14. 2005
    ....
  16. ncbi Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule
    Timothy Madden
    Pharmaceutical Development Center, The University of Texas MD Anderson Cancer Center, Houston, Texas 770554, USA
    Biol Blood Marrow Transplant 13:56-64. 2007
    ..8 mg/kg) to 130 mg/m2 (approximately 3.2 mg/kg). Further, once-daily intravenous busulfan dosing is convenient, favoring its more widespread application...
  17. ncbi Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation
    Marcos de Lima
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 104:865-72. 2004
    ..Survival was improved for patients in CR at transplantation. In conclusion, FM provided better disease control though at a cost of increased TRM and morbidity...
  18. ncbi Treatment of relapsing refractory diffuse large cell lymphoma after matched unrelated donor bone marrow transplant with immunosuppression withdrawal and rituximab
    Raymond Wong
    Department of Blood and Marrow Transplantation, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 423, Houston, TX 77030 4009, USA
    Leuk Lymphoma 44:829-32. 2003
    ..Lymphoma relapse occurred 4 months post-transplant. Immunosuppression withdrawal plus rituximab induced a complete response. He remains in complete remission (CR) 11 months post-immunosuppression withdrawal and 15 months post-transplant...
  19. ncbi Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival
    Issa F Khouri
    Department of Blood and Marrow Transplantation, M D Anderson Cancer Center, Houston, Tex 77030, USA
    Exp Hematol 32:28-35. 2004
    ..To investigate the graft-vs-leukemia effect of allogeneic stem cell transplantation after a nonablative conditioning regimen as treatment for patients with chronic lymphocytic leukemia...
  20. pmc Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplant
    Qaiser Bashir
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D AndersonCancer Center, Houston, TX, USA
    Leuk Lymphoma 53:915-9. 2012
    ..ATG levels were not associated with clinical outcomes. Thus, our results favor the use of ATG 4.5 mg/kg over ATG 7.5 mg/kg in patients undergoing unrelated donor hematopoietic cell transplant with reduced-intensity conditioning regimens...
  21. ncbi Extracorporeal photopheresis for acute and chronic graft-versus-host disease: does it work?
    Daniel Couriel
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 12:37-40. 2006
    ..All of these results indicate activity of extracorporeal photopheresis in acute and chronic GVHD, which warrants further evaluation of this therapy in well-designed, prospective, controlled studies...
  22. ncbi Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas
    Issa F Khouri
    Department of Blood and Marrow Transplantation, Unit 423, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 23:2240-7. 2005
    ....
  23. ncbi Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: donor type matters
    Maha El-Zimaity
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 423, Houston, TX 77030, USA
    Blood 103:4674-80. 2004
    ..We concluded that HC is more prevalent in MUD and UCB transplantations...
  24. ncbi Rituximab-induced acute liver failure after an allogeneic transplantation for chronic myeloid leukemia
    Muzaffar H Qazilbash
    Department of Blood and Marrow Transplantation, UT MD Anderson Cancer Center, Houston, 77030, USA
    Am J Hematol 80:43-5. 2005
    ..The patient developed autoimmune hemolytic anemia that failed to respond to steroids, intravenous immunoglobulins, and plasma exchange. She was then treated with rituximab that resulted in fatal acute liver toxicity...
  25. ncbi CD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk for graft-versus-host disease after HLA-identical stem cell transplantation in humans
    Marta Stanzani
    Transplant Immunology Laboratory, MD Anderson Cancer Center, SCRB 3 3019, 7455 Fannin St, Houston, TX 77030, USA
    Blood 103:1140-6. 2004
    ....
  26. ncbi Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia
    Borje S Andersson
    Department of Blood and Marrow Transplantation, University of Texas MD Anderson Cancer Center, Houston 77005, USA
    Biol Blood Marrow Transplant 8:477-85. 2002
    ..Given the ability of i.v. Bu to provide a more consistent per-dose AUC, these results should be useful in designing future i.v.V Bu-based treatment protocols for stem cell transplantation...
  27. ncbi Graft-versus-host disease after allogeneic stem cell transplantation: evolving concepts and novel therapies including photopheresis
    Krishna V Komanduri
    Transplant Immunology Section, Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 12:1-6. 2006
    ....
  28. ncbi Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation
    Raymond Wong
    Department of Blood and Marrow Transplantation, MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
    Br J Haematol 122:128-34. 2003
    ..One patient was changed to cyclosporine. In most patients, subsequent treatment with tacrolimus was well tolerated without recurrence of neurotoxicity...
  29. ncbi Double-chimaerism after transplantation of two human leucocyte antigen mismatched, unrelated cord blood units
    Marcos de Lima
    Department of Blood and Marrow Transplantation, Pathology, and Leukaemia, M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 119:773-6. 2002
    ..Triple chimaerism was present from relapse until death due to leukaemia. This approach may potentially improve UCB transplantation outcome for adults lacking a histocompatible donor...
  30. ncbi Endoscopic biopsy diagnosis of acute gastrointestinal graft-versus-host disease: rectosigmoid biopsies are more sensitive than upper gastrointestinal biopsies
    William A Ross
    Department of Gastroenterology, Hepatology and Nutrition, The University of Texas M D Anderson Cancer Center, Houston, Texas 77380, USA
    Am J Gastroenterol 103:982-9. 2008
    ..The portion of the GI tract with the highest diagnostic yield is a topic of debate. Our aim was to evaluate the sensitivity of simultaneous biopsy of the stomach, duodenum, and rectosigmoid in establishing the diagnosis of GI GVHD...
  31. doi Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience
    Paolo Anderlini
    The U T M D Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy 1515 Holcombe Boulevard, Unit 423, Houston, TX 77030 USA
    Haematologica 93:257-64. 2008
    ..We here present an update of our single-center experience with fludarabine-melphalan as a preparative regimen...
  32. ncbi Colonic graft-versus-host disease
    William A Ross
    Department of Gastrointestinal Medicine and Nutrition, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Curr Opin Gastroenterol 21:64-9. 2005
    ..Gastrointestinal GVHD frequently involves the colon and complicates management of these seriously ill patients. This review updates the diagnosis and management of colonic GVHD...
  33. ncbi Transplantation's greatest challenges: advances in chronic graft-versus-host disease
    Warren D Shlomchik
    Department of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut, USA
    Biol Blood Marrow Transplant 13:2-10. 2007
    ..In this overview, we address 3 key areas related to chronic GVHD that hold the highest promise for major advances in the near future: pathobiology, response criteria, and therapy...
  34. ncbi Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit
    Borje S Andersson
    Biol Blood Marrow Transplant 9:722-4. 2003
  35. ncbi A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease
    Margaret L Macmillan
    Blood and Marrow Transplant Program, Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA
    Blood 109:2657-62. 2007
    ..This prospective, multicenter, randomized clinical trial for steroid-resistant acute GVHD serves as a model for future evaluation of new agents...
  36. ncbi National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report
    Paul J Martin
    Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, Washington 98109 1024, USA, and Hopital St Louis, Paris, France
    Biol Blood Marrow Transplant 12:491-505. 2006
    ..The use of consistent standards in clinical trial designs to evaluate agents that have activity in pathogenic pathways could facilitate advances in the treatment of chronic GVHD...
  37. ncbi A survey of diagnosis, management, and grading of chronic GVHD
    Stephanie J Lee
    Center for Outcomes and Policy Research, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 8:32-9. 2002
    ..We conclude that studies defining appropriate diagnostic pathways, criteria for disease activity, and prognosis could help standardize management of cGVHD. There is an urgent need to develop and test new approaches to treat cGVHD...
  38. ncbi Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report
    Steven Z Pavletic
    National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1203, USA
    Biol Blood Marrow Transplant 12:252-66. 2006
    ..The proposed response criteria are based on current expert consensus opinion and are intended to improve consistency in the conduct and reporting of chronic GVHD trials, but their use remains to be demonstrated in practice...
  39. ncbi Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report
    Kirk R Schultz
    British Columbia Children s Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    Biol Blood Marrow Transplant 12:126-37. 2006
    ..Both approaches have merit and should be pursued. The consistent treatment and standardized documentation needed to support biomarker studies are most likely to be satisfied in prospective clinical trials...
  40. ncbi National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report
    Alexandra H Filipovich
    Cincinnati Children s Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio 45229, USA
    Biol Blood Marrow Transplant 11:945-56. 2005
    ..It is currently recommended that systemic therapy be considered for patients who meet criteria for chronic GVHD of moderate to severe global severity...
  41. ncbi The graft-versus-leukemia effect in leukemia cutis
    Raymond Wong
    Transplantation 76:619-20. 2003
  42. ncbi Bilateral marginal keratitis associated with engraftment syndrome after hematopoietic stem cell transplantation
    Eric Dai
    Department of Ophthalmology, The University of Texas Medical Branch, Galveston, TX, USA
    Cornea 26:756-8. 2007
    ..To report the first case of bilateral marginal keratitis in the setting of engraftment syndrome in a patient who had undergone hematopoietic stem cell transplantation...